Zusammenfassung
Ähnlich wie für Antidepressiva wird auch bei der Entwicklung von neuen Neuroleptika (Übersicht siehe Tabelle 1) u. a. das Ziel verfolgt, bei gleicher bzw. besserer therapeutischer Wirkung ein günstigeres Nebenwirkungsprofil zu erreichen. Die zur Zeit im Handel befindlichen Neuroleptika unterscheiden sich einerseits hinsichtlich der Stärke und Spezifität der Dopamin-Rezeptorblockade und andererseits hinsichtlich der Wirkung auf weitere Rezeptoren (z. B.: histaminerg, muskarinisch, serotonerg, alpha-adrenerg). Die unterschiedliche Wirkung auf diese Rezeptoren, aber auch auf Dopamin-Subtypen (D1, D2) und dabei deren toposelektive Präferenz bestimmen sowohl die Wirkung als auch das Nebenwirkungsprofil.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Anden NE, Golembiowska-Nikitin K, Thornstrom U (1982) Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively. Naunyn Schmiedebergs Arch Pharmacol 321: 100–104
Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784–794
Amt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60: 205–223
Benkert O, Holsboer F (1984) Effect of sulpiride in endogenous depression. Acta Psychiatr Scand [Suppl] 311: 43–48
Benkert O, Gründer G, Wetzel H (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25: 254–260
Brambilla F, Scarone S, Pugnetti L, Massironi R, Penati G, Nobile P (1983) Bromocriptine therapy in chronic schizophrenia. Effects on symptomatology, sleep patterns and prolactin response to stimulation. Psychiatry Res 8: 159–169
Brücke T, Danielczky W, Simanyi M, Sofic E, Riederer P (1986) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 573–576
Bunzow JR, van Tol HHM, Grandy DK, Alter P, Salon J, Christie M, Machida CA, Neve KA, 238 S. Kasper et al.
Civelli O (1988) Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336: 783–787
Carlsson A (1975) Receptor-mediated control of dopamine metabolism. In: Usdin E, Bunney WE Jr (eds) Pre-and postsynaptic receptors. Marcel Dekker, New York, pp 49–65
Carlsson A (1988) The dopamine hypothesis of schizophrenia 20 years later. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 223–235
Carlsson A (1991) Das antipsychotische Potential von dopaminergen Liganden. In: Beckmann H, Osterheider M (Hrsg) Tropon-Symposium, Bd Vl. Springer, Berlin Heidelberg New York Tokyo, S 135–144
Coward D, Dixon K, Enz A, Sherman G, Urwyler S, White T, Karobath M (1989) Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 25: 393–397
Coward D, Dixon K, Urwyler S (1990) Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208–911 and SDZ 208–912. J Pharmacol Exp Ther 252: 279–285
Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL (1985) Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res 16: 95–99
Fritze J (1992) Neurobiochemie, Wirkungsmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuropsychopharmaka, Bd 4. Neuroleptika. Springer, Wien New York, S 59–80
Gerbaldo H, Demisch I, Lehmann CO, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms. Results of an open study. Pharmacopsychiatry 21: 387–388
Gründer G, Wetzel H, Hammes E, Benkert O (1992) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psy Clin Neuropharm 15 [Suppl 1, Pt B]: 175B
Hinzen D, Hornykiewicz O, Kobinger W, Pichler L, Pifl C, Schingnitz G (1986) The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of parkinson’s disease a novel approach to treatment. Eur J Pharmacol 131: 75–86
Jimerson DC (1987) Role of dopamine mechanisms in the affective disorders. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 505–512
Kasper S, Fuger J, Zimmer HJ, Bäuml J, Möller HJ (1992) Early clinical results with the neuroleptic roxindole (EMD 49980) in the treatment of schizophrenia — an open study. Eur Neuropsychopharmacol 2: 91–95
Kasper S, Fuger J, Möller HJ (1992) Comparative efficacy of antidepressants. Drugs [Suppl] 43: 11–23
Kissling W, Mackert A, Bäuml J, Lauter H (1992) Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919. In: Gaebel W, Laux G (Hrsg) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin Heidelberg New York Tokyo, S 256–249
Klimke A, Klieser E (1991) Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (roxindole). Pharmacopsychiatry 24: 107–112
Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr Bull 6: 456–475
Meltzer HY, Kolakowska T, Robertson A, Tricon BJ (1983) Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy. Psychopharmacology 81: 37–41
Mireau J, Schingnitz G (1991) Biochemical and pharmacological studies on pramipexol, a potent and selective D-2 dopamine receptor agonist. Eur J Pharmacol 136: 12–19
Möller HJ (1992) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3: 1–11
Naher D, Gaussares C, „SDZ HDC 912 Collaborative Study Group“. In: Moegelen JM, Tremmel L, Bailey PE (1992) Wirksamkeit und Verträglichkeit des Dopamin-Agonisten/Antagonisten SDZ HDC 912 in der Therapie schizophrener Patienten. In: Gaebel W, Laux G (Hrsg) Biologische Psychiatrie. Synopsis 90/91. Springer, Berlin Heidelberg New York Tokyo, S 245–249
Olbrich R, Schanz H (1988) The effect of the partial dopamin agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 21: 389–390
Olbrich R, Schanz H (1991) An evaluation of the partial dopamine agonist terguride on negative symptoms in schizophrenia. J Neural Transm [Gen Sect] 84: 233–236
Pichler L, Kobinger W (1981) Centrally mediated cardiovascular effects of B-HT 920 (6-allyl2-amino-5,6 7,8-tetrahydro-4H-thiazolo (4,5-djazepine dihydrochloride), a hypotensive agent of the clonidine type. J Cardiovasc Pharmacol 3: 269–277
Roth RH, Wolf ME, Deutsch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81–94
Serra G, Forgione A, d’Aquila PS, Colin M, Fratta W, Gessa GL (1990) Blockade of DA autoreceptors: possible mechanism of antidepressant action of L-sulpiride. Adv Biosci 77: 185–191
Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41
Seyfried CA, Boettcher H (1990) Central D2-autoreceptor agonists, with special reference to indolylbutylamines. Drugs of the Future 8: 819–832
Sokoloff P, Giros B, Martres MP, Boutenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor ( D3) as a target for neuroleptics. Nature 347: 146–151
Tamminga CA, Schaffer MH, Smith RC (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568
Tamminga CA, Gotts MD, Miller MR (1983) N-propyl-norapomorphine in the treatment of schizophrenia. Acta Pharm Sued [Suppl] 2: 153–158
van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M (1986) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983
Wachtel H, Dorow R (1983) Dual action on central dopamine function of trans-dihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuricle. Life Sci 32: 421–432
Wetzel H, Benkert O (1990) Neuroleptika: Neue Substanzen–Neue Indikation. In: Herz VA, Hippius A, Spann W (Hrsg) Psychopharmaka heute. Springer, Berlin Heidelberg New York Tokyo, S 108–128
Wetzel H, Gründer G, Hillert A, Hiemke C, Benkert O (1993) Neuroendocrinological and EEG sleep effects of Roxindole, a dopamine autoreceptor agonist in schizophrenic and depressed patients. Clin Neuropharm 15 [Suppl 1B]: 602 B
Wetzel H, Hillert A, Gründer G, Benkert 0 (1994) Roxindole a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenia. Am J Psychiatry (im Druck )
Wetzel H, Benkert 0 (1994) Dopamin autoreceptor agonists in the treatment of schizophrenic disorders. Prog Neuropsychopharmacol Biol Psychiatry 17: 525–540
Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920–a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55
Wiedemann K, Loycke A, Krieg JC, Holsboer F (1991) EMD 49980 - a novel dopamine auto-receptor agonist in the treatment of schizophrenic patients with negative symptoms. Biol Psychiatry [Suppl] 29: 422 S
Willner P (1983) Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res Rev 6: 211–224
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag/Wien
About this chapter
Cite this chapter
Kasper, S., Danos, P., Höflich, G., Möller, HJ. (1994). Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik. In: Möller, HJ., Laux, G. (eds) Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9349-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9349-5_19
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82547-1
Online ISBN: 978-3-7091-9349-5
eBook Packages: Springer Book Archive